» Articles » PMID: 37124828

Patterns of Better Breast Cancer Care in Countries with Higher Human Development Index and Healthcare Expenditure: Insights from GLOBOCAN 2020

Overview
Specialty Public Health
Date 2023 May 1
PMID 37124828
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The huge burden of breast cancer (BC) necessitates the profound and accurate knowledge of the most recent cancer epidemiology and quality of care provided. We aimed to evaluate BC epidemiology and quality of care and examine the effects of socioeconomic development and healthcare expenditure on disparities in BC care.

Methods: The results from the GLOBOCAN 2020 study were utilized to extract data on female BC, including incidence and mortality numbers, crude rates, and age-standardized rates [age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs)]. The mortality-to-incidence ratio (MIR) was calculated for different locations and socioeconomic stratifications to examine disparities in BC care, with higher values reflecting poor quality of care and vice versa. In both descriptive and analytic approaches, the human development index (HDI) and the proportion of current healthcare expenditure (CHE) to gross domestic product (CHE/GDP%) were used to evaluate the values of MIR.

Results: Globally, 2,261,419 (95% uncertainty interval (UI): 2,244,260-2,278,710) new cases of female BC were diagnosed in 2020, with a crude rate of 58.5/100,000 population, and caused 684,996 (675,493-694,633) deaths, with a crude rate of 17.7. The WHO region with the highest BC ASIR (69.7) was Europe, and the WHO region with the highest ASMR (19.1) was Africa. The very high HDI category had the highest BC ASIR (75.6), and low HDI areas had the highest ASMR (20.1). The overall calculated value of female BC MIR in 2020 was 0.30, with Africa having the highest value (0.48) and the low HDI category (0.53). A strong statistically significant inverse correlation was observed between the MIR and HDI values for countries/territories (Pearson's coefficient = -0.850, -value < 0.001). A significant moderate inverse correlation was observed between the MIR and CHE/GDP values (Pearson's coefficient = -0.431, -value < 0.001).

Conclusions: This study highlighted that MIR of BC was higher in less developed areas and less wealthy countries. MIR as an indicator of the quality of care showed that locations with higher healthcare expenditure had better BC care. More focused interventions in developing regions and in those with limited resources are needed to alleviate the burden of BC and resolve disparities in BC care.

Citing Articles

Effect of depression and empowerment on medication adherence in patients with breast cancer: a descriptive survey.

Jeong S, Kim E BMC Nurs. 2025; 24(1):47.

PMID: 39806337 PMC: 11731554. DOI: 10.1186/s12912-024-02680-8.


Potential Drug Synergy Through the ERBB2 Pathway in HER2+ Breast Tumors.

Rojas-Salazar Y, Gomez-Montanez E, Rojas-Salazar J, Anda-Jauregui G, Hernandez-Lemus E Int J Mol Sci. 2024; 25(23).

PMID: 39684551 PMC: 11641395. DOI: 10.3390/ijms252312840.


The effects of Tai Chi and Baduanjin on breast cancer patients: systematic review and meta-analysis of randomized controlled trials.

Chen Y, Zuo X, Tang Y, Zhou Z Front Oncol. 2024; 14:1434087.

PMID: 39529823 PMC: 11551136. DOI: 10.3389/fonc.2024.1434087.


Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition.

Lo Y, Hong C, Wang C, Yang C Arch Pharm Res. 2024; 47(10-11):829-853.

PMID: 39482441 PMC: 11602847. DOI: 10.1007/s12272-024-01514-0.


Effects of web-based interventions on quality of life among patients with breast cancer: A systematic review and meta-analysis of randomized controlled trials.

Coombs L, Kim M Cancer Med. 2024; 13(18):e70230.

PMID: 39359165 PMC: 11447276. DOI: 10.1002/cam4.70230.


References
1.
Dreyer M, Nattinger A, McGinley E, Pezzin L . Socioeconomic status and breast cancer treatment. Breast Cancer Res Treat. 2017; 167(1):1-8. PMC: 5790605. DOI: 10.1007/s10549-017-4490-3. View

2.
Sharma R . Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018. Breast Cancer Res Treat. 2021; 187(2):557-567. DOI: 10.1007/s10549-020-06083-6. View

3.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

4.
Ataeinia B, Moghaddam S, Shabani M, Gohari K, Sheidaei A, Rezaei N . National and Subnational Incidence, Mortality, and Years of Life Lost Due to Breast Cancer in Iran: Trends and Age-Period-Cohort Analysis Since 1990. Front Oncol. 2021; 11:561376. PMC: 8027299. DOI: 10.3389/fonc.2021.561376. View

5.
Igene H . Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J. 2008; 14(5):428-34. DOI: 10.1111/j.1524-4741.2008.00618.x. View